New blood test could spot fetal chromosomal issues earlier and more accurately
NCT ID NCT03375359
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a cell-free DNA blood test to screen for trisomy 21, 18, 13 and 22q11.2 deletion in over 1,100 pregnant women during the first trimester. The goal was to see how accurate the test is compared to standard combined screening. Researchers measured how often the test gave a positive result, a false positive, or no result at all.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could improve early detection of chromosomal abnormalities in pregnancy, reducing false positives and unnecessary invasive tests.
- What could go wrong
- This is a completed diagnostic accuracy study, not a treatment trial. Results may not apply to all populations or screening settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Tuebingen, Department of Women's Health
Tübingen, 72076, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a class tame pregnancy stress at the genetic level?
- A nationwide test: do home visits build healthier families?
- Can a simple calcium tablet help prevent postpartum bleeding?
- Can AI read ultrasound sweeps to tell Baby's position?
- Could a smart ring unlock secrets of pregnancy health?
- Could Video-Led pelvic exercises redefine prenatal care?